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Several researchers have shown that infant
exposure to dioxin-like compounds can be
signiﬁcant by the breast milk pathway (1–4).
Ayotte et al. (1) used data on the concentra-
tions of dioxin-like compounds [including
dioxin and furan congeners as well as the
dioxin-like polychlorinated biphenyls
(PCBs)] in breast milk of Inuit populations
in Nunavik (the Arctic region of Quebec,
Canada) with a median concentration of 48
pg dioxin toxic equivalents (TEQ)/g lipid, to
calculate an infant dose of 226 pg TEQ/kg-
day. They applied a pharmacokinetic (PK)
model to evaluate the impact of breast-feed-
ing of dioxin TEQs on infant body burdens
and on lifetime (up to 75 years) body bur-
dens of TEQs. By studying the accumulation
of dioxin-like compounds in humans over
time, Patandin et al. (2) showed that 6
months of breast-feeding during the ﬁrst 25
years of life could contribute 12% of the total
dose of these compounds during those 25
years for men and 14% for women. Kreuzer
et al. (3) and Lakind et al. (4) combined esti-
mates of 2,3,7,8-tetrachlodibenzo-p-dioxin
(TCDD) dose received by the infant via
breast-feeding with PK models to demon-
strate the initial signiﬁcant elevation in infant
body burdens of TCDD as a result of this
exposure. Their models predicted that ini-
tially high body burdens declined as a result
of infant body weight increases, depuration
of residues, and reduced doses due to declines
of residues of TCDD in mother’s milk. 
In this paper, we build on the efforts of
other researchers (1–4) to model the impacts
of breast-feeding on body burdens of dioxin-
like compounds. We express body burdens
in terms of picograms of dioxin TEQs per
gram body lipid or parts per trillion TEQ
lipid; these compounds are known to accu-
mulate in lipid, and TEQ concentrations in
mother’s milk, blood, and other organs are
often expressed on a lipid basis. 
In this paper we focus on dioxin-like
compounds expressed as a dose or concen-
tration of dioxin TEQs. The TEQ concen-
tration is the sum of the concentrations of
the individual dioxin-like compounds multi-
plied by their respective toxicity equivalency
factors (TEFs). The TEF scheme we used is
the one promoted by the World Health
Organization in 1998 (5). We use TEQ to
signify the 29 compounds assumed to have
dioxin-like toxicity, including the 7 poly-
chlorinated dibenzo-p-dioxin (PCDD) and
10 dibenzofuran (PCDF) congeners, as well
as the 12 dioxin-like coplanar PCBs, unless
otherwise stated. We treat TEQs as a single
compound. Even with the principal uncer-
tainty of this approach, the limited valida-
tion and general comparison of modeled
results with the measured values suggest that
this may be a reasonable approach for evalu-
ating trends in exposure to dioxin-like com-
pounds via breast-feeding. 
In this paper we describe and validate a
simple pharmacokinetic model for evaluating
the impact of breast-feeding on infant body
burdens. We then apply the model to five
scenarios: formula only, and nursing times of
6 weeks, 6 months, 1 year, and 2 years. We
also performed another sensitivity analysis
test that doubled the dose received by the
infant and also doubled the infant’s initial
body burden at birth to determine how these
parameters affect model predictions. 
Modeling the Impact of Breast-
Feeding on Infant Body Burden
To better evaluate the impact of nursing on
infants, we used a one-compartment non-
steady state PK model to predict dioxin tissue
levels in infants. The PK model is based on
the following differential equation describing
the mass balance of dioxin in lipids (6):
∂a(t)/∂t = abs D(t) – k(t)a(t) [1]
c(t)=   a(t)/[1,000 V(t)], [2]
where a(t) is the total mass of dioxins in
lipid (picograms) at time t; t is time (days);
abs is the fraction of ingested dose that is
absorbed into the lipid compartment (unit-
less); D(t) is the ingested dose of TEQs
(picograms per day) at time t, k(t) is the
elimination rate function (per day) at time t;
c(t) is the concentration of dioxins in lipid
(picograms per gram) at time t; and V(t) is
the lipid weight (kilograms) at time t. 
This modeling framework, as well as the
parameter assignments we used in this study,
derive heavily from the efforts of Lakind et al.
(4) and Kreuzer et al. (3). Lakind et al. (4)
also used a first-order, single compartment
model to predict the accumulation of TCDD
and dichlorodiphenyldichloroethane (DDE)
in infants from breast-feeding. Lakind
reviewed the literature to assign critical
model parameters that are also required in
our study, such as the absorption of ingested
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We used a one-compartment, ﬁrst-order pharmacokinetic model to predict the infant body bur-
den of dioxin-like compounds that results from breast-feeding. Validation testing of the model
showed a good match between predictions and measurements of dioxin toxic equivalents (TEQs)
in breast-fed infants, and the exercise highlighted the importance of the assumption of the rate of
dissipation of TEQs in the infant. We evaluated ﬁve nursing scenarios: no nursing (i.e., formula
only), and nursing for 6 weeks, 6 months, 1 year, and 2 years. We assumed that an infant weighs
3.3 kg at birth and is exposed to a total of 800 pg TEQ/day by consumption of breast milk, lead-
ing to an estimated body weight-based dose of 242 pg TEQ/kg-day, which drops to 18 pg
TEQ/kg-day after 1 year. This decline is due to declines in dioxin concentration in mother’s milk
and infant body weight increases. This range is signiﬁcantly higher, on a body-weight basis, than
adult TEQ exposure, which has been estimated to average about 1 pg TEQ/kg-day. For the nurs-
ing scenarios of ≥ 6 months, we predict that body burdens (expressed as a body lipid concentra-
tion) peak at around 9 weeks at 44 ppt TEQ lipid. We predict that the body burden of the
formula-fed infants will remain below 10 ppt TEQ lipid during the ﬁrst year. These results com-
pare to the current adult average body burden of 25 ppt TEQ lipid. We also found that an infant
who had been breast-fed for 1 year had an accumulated dose 6 times higher than a 1-year-old
infant who had not been breast-fed. For a 70-year lifetime, individuals who had been breast-fed
had an accumulated dose 3–18% higher than individuals who had not been breast-fed. Key
words: breast milk, dioxin-like compounds, dioxins, furans, infant exposure, pharmacokinetic
modeling. Environ Health Perspect 110:A325–A332 (2002). [Online 13 May 2002]
http://ehpnet1.niehs.nih.gov/docs/2002/110pA325-A332lorber/abstract.html
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absorption of TCDD, whereas the literature
that we reviewed for this work suggests a
lower absorption for TEQ intakes (80%).
Lakind et al. (4) also reviewed the literature
to develop a model of declining concentra-
tions in mother’s milk. We used the same
justification in this study to consider this
decline. A key input to the Lakind model (4),
as in our model, is a ﬁrst-order rate of elimi-
nation; Lakind et al. (4) used an elimination
rate derived by Kreuzer et al. (3). The Lakind
model, like our model, does not model any
specific process of TCDD elimination; it
simply requires assignment of a first-order
elimination rate. Kreuzer et al.’s model (3)
was slightly more complex and more physio-
logically based than the model of Lakind et
al. (4) and the one we used in this study.
Specifically, ingested TCDD is deposited
into body adipose tissue, from which it parti-
tions into richly perfused tissue (a single
compartment composed of brain, kidney,
intestines, liver, and spleen) and instanta-
neously into muscle tissue. Elimination of
TCDD is modeled as the sum of metabolic
(breakdown) and nonmetabolic (fecal elimi-
nation) pathways. We estimated fecal elimi-
nation as the product of the lipid tissue
concentration and the mass of lipids excreted
over time. Using physiologic data on the
mass of lipids in fecal samples that varied
with age, Kreuzer et al. (3) found that the
overall half-life of TCDD in infants was dri-
ven by fecal elimination. This overall half-life
was on the order of weeks at infancy, and it
increased through infancy until the metabolic
pathway dominated in adulthood. The over-
all half-life of TCDD in adults was more on
the order of years rather than weeks.
One key assumption of this simplistic
framework is that dioxins are instantaneously
distributed to all body lipids. This is a com-
mon assumption for TCDD PK modeling in
humans, adopted in multicompartment (7)
and single-compartment (3,4,8) models. The
model of Carrier et al. (9,10) alternately has a
nonlinear response to doses, with different
partitioning to the liver and other body lipids
as a function of body concentration: when
the overall body concentration is high, more
of the dioxin dose is partitioned to the liver,
whereas at lower body concentrations, the
partitioning to the liver is lower. 
The other key assumption in our model
is that a dioxin TEQ dose behaves as a single
compound in humans and is described by a
single dissipation half-life. Ayotte et al. (1)
modeled TEQ body burdens from infancy
to adulthood, but it was unclear whether
they modeled individual congeners or TEQs
as one compound. Campbell et al. (8) used a
framework similar to the one we used and
modeled individual congeners for an indus-
trial exposure study. 
An elimination rate function, k(t), for
TCDD has been modeled as a function of
the percent body fat, k(fat) (6,11,12). This
empirical function, k(fat), was curve-ﬁt from
data on Vietnam veterans (11) who had
approximately 25% body fat. As the percent-
age of body fat increases, the elimination rate
is modeled to decrease (equivalently, the
half-life is modeled to increase) signiﬁcantly.
Given a range of body fat over a lifetime,
from a low of 15% (teenage years) to a high
of over 40% (elderly females), these relation-
ships suggest a half-life of TCDD ranging
from approximately 6 years to > 20 years,
with a general trend toward an increase in
half-life as individuals age (because the per-
centage of body fat increases with age). 
None of these efforts, however, identi-
fied processes or factors critical for infants.
With a body fat of around 15% at birth, the
half-life of TCDD is approximately 6 years
using these k(fat) relationships. Kreuzer et
al. (3), however, developed a procedure for
modeling the overall elimination half-life for
TCDD in infants that considers metabolic
(tm; breakdown by enzymes) and nonmeta-
bolic (tf ; fecal elimination) processes. Other
key parameters included total body lipid
mass and liver volumes, which change over
time, and a reference half-life for an adult.
For their “reference adult” at 40 years of
age, Kreuzer et al. (3) cited an overall half-
life of 5 years, based on information from
Geyer et al. (13). The Kreuzer et al. (3)
model showed a rise in half-lives from a low
of < 0.5 years at birth to a high of 5 years at
an adult body fat mass of 20 kg. Thus, the
model of Kreuzer et al. (3) is different than
the k(fat) models (6,11,12): the model of
Kreuzer et al. (3) predicts half-lives that
never exceed 5 years, whereas the other
approaches predict half-lives that never go
below 6 years. 
For purposes of this assessment, we
assumed that the overall half-life for the early
years of life more closely follows the trend as
derived in the modeling exercises by Kreuzer
et al. (3). For later years, we believe that the
k(fat) model is more valid. Therefore, for this
study, we adopted a hybrid of these assump-
tions, as shown in Figure 1; point estimates of
the half-life [the model parameter, k(t), equal
to 0.693/half-life] are shown in Table 1. The
half-life at birth starts at the low value of 0.4
years and then slowly rises to the levels pre-
dicted by the k(fat) models by approximately
25 years of age. The half-life assumptions
remain an obvious uncertainty for this type of
modeling approach. Not only is there a dis-
parity in the literature with regard to this crit-
ical assumption, but the literature was only
speciﬁc to TCDD, not TEQs. 
Using the estimated dioxin concentra-
tion in breast milk, the dose to the infant
was modeled as follows:
D(t) = C(t) f IR, [3]
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Figure 1. Comparison of the selected half-life of
TEQs in the body with lipid-based half-life (6) and
modeled half-life (3) for TCDD.
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Table 1. Parameters used for modeling the impact of breast-feeding on body burden and lipid concentra-
tions of TEQs from infancy to adulthood.
PK modeling parameters Dioxin TEQ dose (pg/day)
Half-life Breast-fed
Age BW (kg) Lipida (years)b Formula 6 weeks 6 Months 1 Year 2 Years
Birth 3.3 0.14 0.40 54 800 800 800 800
1 Month 4.3 0.16 0.50 54 733 733 733 733 
2 Months 4.6 0.18 0.60 54 667/54  667  667 667
3 Months 6.0 0.20 0.70 54 54 600 600 600
4 Months 6.7 0.22 0.75 54 54 533 533 533
5 Months 7.4 0.23 0.80 54 54 467 467 467
6 Months 7.9 0.25 1.00 54 54  400 400 400
7 Months 8.4  0.25 1.00 54 54 54 367 367
8 Months 8.8 0.24 1.05 54 54 54 333 333
9 Months 9.2 0.24 1.08 54 54 54 300 300
10 Months 9.4 0.23 1.10 54 54 54 267 267
11 Months 9.8 0.23 1.12 54 54 54 233 233
1 Year 11.3 0.23 1.14 54 54 54 200 200
2 Years 13.3 0.20 1.39 54 54 54 54 200
5 Years 19.7 0.15 2.12 59 59 59 59  59
11 Years 41.1 0.15 3.60 64 64 64 64 64
18 Years 65.1 0.13 5.33 65 65 65 65 65
34 Years 71.5 0.21 7.70 65 65 65 65 65
55 Years 73.8 0.27  9.76 65 65 65 65 65
BW, body weight.
aFraction of body weight that is lipid. bHalf-life of dioxin residues in body.where D(t) is the ingested dose of TEQs
(picograms per day) at time t, C(t) is the
concentration in milk fat (picograms per
gram), f is the fraction of fat in breast milk,
IR is the ingestion rate of breast milk (kilo-
grams per day), and t is time. The dose term,
D(t), can easily be converted to a body
weight-based dose term by dividing by
infant body weight. The milk fat concentra-
tion and the infant body weight were mod-
eled to vary over time; we assumed that the
rate of ingestion of mother’s milk and the
fraction of fat in the mother’s milk were
constant over the duration of breast-feeding. 
Smith (14) reported that studies in Great
Britain and Houston, Texas, found that the
breast milk ingestion rate for 7- to 8-month-
old infants ranged from 677 to 922 mL/day
and 723 to 751 mL/day, respectively, and
that breast milk ingestion rates remain rela-
tively constant over an infant’s life. Smith
(14) also assumed that mother’s milk has a
4% fat content and that 80% of the ingested
dioxins in mother’s milk are absorbed. We
adopted these assumptions for the modeling
exercise described in this paper: abs = 0.80,
IR = 0.8 kg/day (which assumes 1 L milk
weighs 1 kg), and f = 0.04. Lakind et al. (4)
reviewed additional literature to support a
selection of 95% for absorption of TCDD
from breast milk ingestion. However, there
is evidence that the absorption is lower as the
degree of chlorination increases, particularly
for the highest chlorinated congener,
octachlorodibenzo-p-dioxin (OCDD), with
an absorption measured to be between 2%
and 15% (15). Because TEQ doses are dom-
inated by the lower chlorinated congeners,
the low absorption of higher chlorinated
congeners may be less critical, justifying the
selection of 0.80 for abs for TEQ doses. 
The lipid weight of the individual, V(t),
was calculated as the product of the fraction
of body lipid and the full body weight of the
individual. A typical infant (average of male
and female) weighs about 3.3 kg at birth, 7.9
kg at 6 months, and 11.3 kg at 1 year of age
(16,17). For dose calculation and PK model-
ing in this study, we averaged monthly aver-
age weights for males and females for the ﬁrst
12 months of life and then for later years into
adulthood (16). The body lipid fraction is
about 0.15 at birth. It then increases to > 0.20
within 6 months, decreases into childhood,
and increases again through adulthood to
> 0.30 after 60 years of age (17). Point esti-
mates of full body weight and lipid fraction as
a function of age are shown in Table 1.
The last parameter for the model is the
initial body burden in infants at birth. We
assumed that this initial body burden is 10
ppt TEQ lipid, reasonably similar to the
11.9 ppt TEQ lipid found in stillborn adi-
pose tissue by Kreuzer et al. (3), although
their TEQ concentration included only
dioxin and furan congeners. 
Impact of Breast-Feeding on
Infant Body Burden and a
Limited Model Validation
Kreuzer et al. (3) presented data on adipose
tissue and liver from 3 stillborn infants and
17 infants who had died from sudden infant
death syndrome (SIDS). Nine of the 17
infants had been breast-fed for some portion
of their lives, whereas the other 8 infants
were formula-fed. Average congener and
TEQ adipose tissue concentrations for these
three groups are shown in Table 2. The
highest TEQ concentrations were found in
the infants who had been breast-fed, with
lipid concentrations of 15.9 ppt TEQ
(PCDD/PCDF only), compared to formula-
fed infants who had concentrations of 4.3
ppt TEQ lipid. All congener concentrations
in breast-fed infants were higher than those
for formula-fed infants. The concentrations
from breast-fed infants included 4 infants
who were weaned several weeks before their
deaths from SIDS. This may have generally
led to reductions in their body burdens
because their higher daily intake from breast-
feeding was reduced after weaning. The
average TEQ concentration for the 5 infants
who died while still breast-feeding was 20.1
ppt TEQ lipid. The highest concentration
found, 35 ppt TEQ lipid, was for the infant
who was breast-fed the longest (19 weeks)
and who died at that time. Other breast-fed
infants, however, did not have as much
impact: infants who died at 12 and 16
weeks, while still breast-feeding, had concen-
trations of 9 and 7.5 ppt TEQ lipid, respec-
tively. Kreuzer et al. (3) concluded that
breast-fed infants had elevated TEQ concen-
trations compared to formula-fed infants;
they also observed that breast-fed infants had
lipid TEQ concentrations that were within
the range or lower than the values published
for adults. 
Abraham et al. (18) reported a study in
Germany in which blood samples from 80
breast-fed infants between 4 and 11 months
of age were sampled for 17 dioxin-like
PCDD/PCDFs. Of these 80 infants, 27 were
from a region where a copper recycling plant
led to elevations in the mother’s milk. The
TEQ blood concentration in this group of 80
children at 11 months of age ranged between
2 and 107 ppt lipid, with a median of 25.3
ppt; these TEQs were based only on
PCDD/PCDF and were calculated using the
older international toxicity equivalency
scheme (18). Of these children, 6 had TEQ
concentrations > 50 ppt lipid, and 5 of these
6 were from the region affected by the copper
recycling plant. From a control group of 21
children who had been formula-fed, individ-
ual dioxin measurements were performed in 5
children. Concentrations ranged from 1.9 to
3.2 ppt TEQ lipid at 11 months of age. 
Patandin et al. (19) studied the plasma
levels of 4 PCBs in 173 Dutch children who
were 3.5 years of age, 91 of whom had been
breast-fed and 82 formula-fed. Children in
the breast-fed group had signiﬁcantly higher
median PCB levels in plasma (p < 0.0001)
than children in the formula-fed group. The
four PCBs measured by Patandin et al. (19)
were PCBs 118, 138, 153, and 180. The
median sums of these four PCBs in the two
groups of children were 0.75 µg/L in the
breast-fed group versus 0.21 µg/L in the for-
mula-fed group. By means of an extensive
questionnaire on dietary history combined
with data on concentrations of dioxin and
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Table 2. Average adipose tissue concentrations of dioxins and furans in stillborn, formula-fed, and breast-
fed infants (pg/g lipid).
Stillborn Formula-fed Breast-fed 
Compound (n = 3) (n = 8) (n = 9)
TCDD 1.6 0.4 1.7
1,2,3,7,8-PentaCDD 3.4 1.1 4.9
1,2,3,4,7,8-HexaCDD 2.5 1.0 4.0
1,2,3,6,7,8-HexaCDD 8.8 4.0 19.9
1,2,3,7,8,9-HexaCDD 1.3 0.7 3.7
1,2,3,4,6,7,8-HeptaCDD 12.9 5.0 25.2
OCDD 51.2 29.1 91.6
2,3,7,8-TCDF 1.4 1.9 1.1
1,2,3,7,8,-PentaCDF 0.2 1.0 0.5
2,3,4,7,8-PentaCDF 9.2 3.1 10.6
1,2,3,4,7,8-HexaCDF 3.7 1.7 3.5
1,2,3,6,7,8-HexaCDF 2.4 1.0 2.8
2,3,4,6,7,8-HexaCDF 1.0 0.2 1.1
1,2,3,7,8,9-HexaCDF 0.1 0.1 0.1
1,2,3,4,6,7,8-HeptaCDF 3.6 1.6 3.8
1,2,3,4,7,8,9-HeptaCDF 0.4 0.1 0.1
OCDF 2.1 1.8 1.6
TEQ 11.9 4.3 15.9
Data from Kreuzer et al. (3). Average congener concentrations were calculated by assuming that nondetects equal one-half
the detection limit.PCBs in food provided by the Dutch
National Institute of Public Health and the
Environment, they were able to determine
that the TEQ intake via diet was virtually
indistinguishable in the two groups. They
found that PCB levels in the breast-fed chil-
dren were significantly correlated with the
period of breast-feeding (r = 0.63), milk
PCB levels (r = 0.39), and the total TEQ in
breast milk (r = 0.36). Patandin et al. (19)
concluded that PCB levels in Dutch children
are the result of exposure through breast
milk and in utero exposure and that the
influence of dietary intake of PCBs after
weaning is small compared to the intake
during breast-feeding. 
Abraham et al. (20,21) sampled blood
from formula-fed and breast-fed infants for
dioxins, furans, and PCBs. Results showed
that the body burden of dioxin-like com-
pounds was more than an order of magni-
tude higher for the breast-fed infants than
the formula-fed infants during both time
periods. PCDD/PCDF TEQ concentrations
ranged from 34.7 ppt lipid (11 months) to
43.9 ppt lipid (25 months) in breast-fed
infants compared to 2.7–3.3 ppt TEQ lipid
for the formula-fed infants. Dioxin-like PCB
concentrations were also an order of magni-
tude different, with the breast-fed infants
having a concentration of 31.4 ppt TEQ
lipid compared to 2.5 ppt TEQ lipid for the
formula-fed infants at 11 months. (PCB 126
was not measured at 25 months, so a com-
parison for that age is not informative.) The
increase in the lipid-based PCDD/PCDF
TEQ concentration in the blood of the 25-
month-old breast-fed infants was attributed
to the relative decrease in body fat mass dur-
ing the period between sampling and slight
increases in body burden concentrations. 
These studies demonstrate the impact of
breast-feeding, but they do not contain the
type of information needed for model valida-
tion. For the data to be appropriate for
model validation, breast milk concentrations
should be taken at the same time infant body
burden measurements are taken. The breast
milk concentrations are used to provide the
“independent” model driving term (the dose
term), and the body burden measurements
provide the “dependent” model prediction
(the infant body lipid concentration).
One study included this type of data.
Abraham et al. (22) studied PCDD/PCDF/
PCB levels in blood of six breast-fed infants
and breast milk from the infants’ mothers. A
portion of this data was reported in their ear-
lier articles (20,21). In our analysis, we focus
on the PCDD/PCDF TEQ concentrations
reported in Abraham et al. (22) because PCB
concentrations were not uniformly available
for mother’s milk and infant blood for all six
mother/child pairs. 
Two of the infants were the second chil-
dren from mothers whose ﬁrst child was also
tracked by Abraham and colleagues (20,21).
For these two second children, both the
mothers’ milk and the infants’ body burdens
were significantly lower; specifically, the
comparison of first and second children,
respectively, were 34.7 ppt TEQ lipid com-
pared to 11.9 ppt TEQ, and 44.2 ppt TEQ
compared to 18.8 ppt TEQ. The compari-
son of the mothers’ milk from the first to
second children was similarly disparate: the
first mother had concentrations ranging
from 14 to 24 ppt TEQ lipid for the first
child, but 13 to 14 ppt TEQ lipid for the
second child. The other mother showed a
range of 15–27 ppt TEQ lipid for the first
child, but 13–18 ppt TEQ lipid for the sec-
ond child. Apparently, breast-feeding of the
first child resulted in higher body burdens
for this infant compared to the second infant
and a lower body burden for the mother
when the second infant was born. 
Table 3 shows the results of the model
validation excercise based on data reported by
Abraham et al. (22). Abraham et al. (22) mea-
sured concentrations in breast-milk two times
for 5 of 6 children. The one child whose
mother had only one measurement was
breast-fed for only 7 weeks; all other children
were breast-fed for 26–32 weeks. We linearly
extrapolated concentrations within the breast-
feeding period from the two available data
points. For example, for the ﬁrst mother/child
pair listed in Table 3, the mother’s milk was
analyzed during month 2 and month 11 after
the child’s birth; TEQ concentrations were
23.5 and 14.0 ppt TEQ lipid, respectively.
We extrapolated these concentrations back-
ward to give an estimated concentration of
24.6 ppt TEQ at birth. Likewise, forward
extrapolation gave an estimated TEQ concen-
tration of 22.4 ppt TEQ for month 3, assum-
ing linear decline. The infant body burden
was determined by blood measurements at
approximately 1 year of age for each child.
Abraham et al. (22) also provided the amount
of time of full breast-feeding (Table 3). 
For modeling the infant body burden, we
assumed that the IR for mother’s milk is 800
mL/day. After weaning, we assumed that the
infant’s dose was 54 pg TEQ/day. This is the
dose developed for the age range of 1–5 years
by the U.S. EPA (23). Little information is
available on the dioxin content of baby for-
mula and baby food; therefore, it is not
known whether the dioxin dose consumed by
infants in formula or other foods after wean-
ing may be higher or lower than the assumed
54 pg/TEQ/day.
The rate of dissipation of dioxin residues
is a principal uncertainty for this model. Two
possibilities include the rapid dissipation
(half-life < 1 year) of TCDD residues in
infants (3,4) and the much longer half-life of
around 7 years, based on a model of half-life
as a function of body fat (6,11,12). This
model validation exercise tested the appropri-
ateness of the lower half-life approach
adopted in this model, as shown in Figure 1,
against an assumption of a constant 7-year
half-life for TEQs during the ﬁrst year of life. 
As shown in Table 3, the model predic-
tions at the selected dissipation rate (half-life
<1   year) were signiﬁcantly nearer to obser-
vations than the predictions with the longer
half-life. The average predicted concentra-
tion for the rapid dissipation rate for the six
infants was 26 ppt TEQ lipid compared to
the average observed concentration of 23.5
ppt TEQ lipid. With a 7-year half-life, the
predicted concentrations were all higher,
with an average of 39 ppt TEQ lipid. The
model, applied with the shorter half-life, also
seemed adequately responsive to lower or
higher exposures in infants. For the infant
who was breast-fed for only 7 weeks with a
low concentration in the mother’s milk, the
blood concentrations were 5.0 ppt TEQ
lipid at 13 months of age compared to a pre-
dicted 10 ppt TEQ lipid. The infant who
was exposed to the highest dioxin concentra-
tion in breast milk had the highest body bur-
den measurement (44.2 ppt TEQ lipid) and
also the highest predicted concentration (36
ppt TEQ lipid).
Mini-Monograph • Lorber and Phillips
A 328 VOLUME 110 | NUMBER 6 | June 2002 • Environmental Health Perspectives
Table 3. Model validation data and results (pg TEQ/g lipid).
Observed dataa Model predictions, child TEQ Cb
Milk TEQc Selected HL Long HL
Description 1st 2nd Child TEQb Weeks BFd < 1 yeare 7 yearsf
Mother 1, 1st child 23.5 (2) 14.0 (11) 34.7 (11) 26 34 51
Mother 1, 2nd child 13.7 (2) 12.7 (5) 11.9 (11) 29 27 39
Mother 2, 1st child 26.5 (2) 15.2 (11) 44.2 (12) 30 36 56
Mother 2, 2nd child 18.3 (2) 13.1 (6) 18.8 (12) 32 27 41
Mother 3, only child 13.7 (2) NA 5.0 (13) 7 10 16
Mother 4, only child 12.7 (2) 13.0 (6) 26.5 (12) 30 21 32
Average C (pg/g TEQ) 23.5 26 39
Abbreviations: BF, breast-fed; C, concentration. Values in parentheses indicate the month after birth when sampling was
performed. 
aData from Abraham et al. (22). bConcentration of TEQ in blood of infants. cBreast milk TEQ concentration. dWeeks of full
breast-feeding. eHalf-life model selected for model validation and further analysis. fAlternate half-life model in which
half-life was 7 years at birth.Even with the key uncertainties identi-
fied above, including the use of a simple,
one-compartment PK model and the model-
ing of dioxin TEQs as though TEQ were a
single compound, this approach appears to
predict infant TEQ body burdens within the
range observed and is adequately responsive
to the different conditions of high and low
exposure via breast-feeding. 
This model validation exercise demon-
strated the importance of half-life to pre-
dictions of infant TEQ body burden
concentrations and the apparent validity of
the short half-life for infants in contrast to
the half-life on the order of years that appears
to be valid for adults. At least in the context
of this simple model, it would not be appro-
priate to assign half-lives on the order of years
for infant body burden modeling. Besides this
half-life, model predictions of infant body bur-
den are most impacted by the dose of TEQs
infants receive through breast milk or other-
wise. The model responds linearly to changes
in dose—if the dose taken in by the infant
doubles, the infant body burden predictions
double. Obviously, the initial concentration of
TEQs in the infant is also affected by the
mother’s body burden. The remaining para-
meters are the infant physiologic parameters
determining the size of the lipid reservoir into
which the ingested dioxins deposit, the chang-
ing infant body weight and lipid fraction. The
model responds in an inverse linear manner to
these parameters—if the reservoir size is
halved, the concentration doubles. There is
realistically not a large range for these parame-
ters and the average values selected below are
probably sufﬁcient for most assessment needs.
The dose is simply a picogram TEQ per
day quantity taken in by the infant, which is
determined externally; the model requires
only the picogram TEQ per day input. It is a
function of the amount of milk a child
drinks, the lipid content of the mother’s milk,
the TEQ concentration in the milk, the frac-
tion of ingested dioxin that is absorbed, and
any other assumptions the user may make
regarding the decline or rise in mother’s milk
concentration (or changes to lipid content of
the milk) over time. We conducted several
model runs to evaluate different nursing sce-
narios. We selected midrange values for all of
the dose model parameters; only the time of
nursing varied. We expected that this exercise
would reasonably bound the exposures the
majority infants in the United States would
receive. Some mothers could have high TEQ
body burdens because of an unusual or occu-
pational exposure. To evaluate this possibility,
we conducted a sensitivity test to evaluate the
effect of doubling the mother’s body burden,
which resulted in not only a doubling of dose
but also inﬂuenced the initial concentrations
of TEQs in the infant.
Scenario Development and
Evaluation
We used this modeling framework to evaluate
ﬁve breast-feeding scenarios: formula-feeding
only or breast-feeding for 6 weeks, 6 months,
1 year, or 2 years. These scenarios encompass
current trends. In a comprehensive documen-
tation of statistics for children born between
1990 and 1993, the Centers for Disease
Control and Prevention (24) reported that
55% of all babies breast-fed, with about one-
half breast-feeding longer than 5 months. The
average duration of breast-feeding was 28.7
weeks. In a policy statement, the American
Academy of Pediatrics (25) stated that exclu-
sive breast-feeding is ideal nutrition and is suf-
ficient to support optimal growth and
development for 6 months after birth. They
recommend that breast-feeding continue for
at least 12 months, and thereafter for as long
as mutually desired.
To model these scenarios, it was impor-
tant to assign values to the mother’s milk
concentration regime over the breast-feeding
period. This regime includes the assignment
of an initial concentration and a scheme to
model the expected decline over time. We
assumed that the dioxin concentration in
breast milk is 25 ppt TEQ lipid when lacta-
tion begins. This is the current average adult
tissue concentration derived in the U.S.
EPA’s draft dioxin reassessment (23) from
recent studies of dioxins in blood in back-
ground settings of the United States. By
adopting this concentration as the initial
concentration in breast milk, we assume that
lipid concentrations of TEQs are equal in
different lipid reservoirs and that a lipid-
based blood concentration is equal to the
lipid-based breast milk concentration, an
assumption that is reasonably well recog-
nized in the literature (23). 
More importantly, however, the 25 ppt
TEQ initial concentration in mother’s milk
can also be characterized as conservative
because it is higher than is currently likely for
the average U.S. woman of child-bearing age.
The average adult concentration of 25 ppt
TEQ lipid includes younger and older adults.
It has been well established in the literature
that dioxin exposures were higher during the
middle decades of the 20th century than they
are now (6,23,26) and that body burdens in
older individuals are currently significantly
higher than in younger individuals. It is likely
that women of child-bearing age in the
United States now have average body bur-
dens < 25 ppt TEQ lipid, probably < 20 ppt
TEQ lipid. However, it is also likely that
there are populations with concentrations
higher than this overall average. For example,
concentrations of dioxin-like compounds in
the blood of sport fishers and nonfishers in
the Great Lakes region were higher, on aver-
age, than 25 ppt TEQ, and higher concentra-
tions were found in sport ﬁshers as compared
to nonﬁshers (27–29).
The concentration of dioxin in breast
milk is expected to change because lactation
provides a signiﬁcant avenue of depuration.
Therefore, the scenarios require an assump-
tion of the decline from the initial breast
milk concentration of 25 ppt TEQ lipid.
Lakind et al. (4) cited several references in
which measurements of breast milk concen-
trations of lipophilic compounds (PCBs,
DDE, DDT, PCDDs/PCDFs) were shown
to decline during the course of lactation.
They ﬁt available data on TCDD to a curve,
and their resulting relationship showed an
86% loss over 6 months. This is comparable
to a modeling effort by Kreuzer et al. (3),
who modeled a 70% decline in TCDD con-
centrations after 6 months. Their model was
more mechanistic than that of LaKind et al.
(4) and added the loss by breast milk to an
overall female body burden model, which
included inputs by food consumption and
outputs by metabolic and nonmetabolic
pathways. Patandin et al. (2), in their model-
ing of dioxin exposures from infancy to
adulthood, cited data from Germany and
England and concluded that breast milk con-
centrations of TCDD decline by 20% every
3 months. The data described in reports by
Abraham et al. (24–26) suggested a TEQ
decline of approximately 40% from early lac-
tation to just under 1 year of breast-feeding. 
Based on this information, we assumed
that the initial 25 ppt TEQ lipid concentra-
tion in breast milk decreased linearly by
50% after 6 months, with a 50% decrease by
the end of 12 months, and a total decline of
75% from initial concentrations. These con-
centration declines are in the middle of the
range reported above. They translate to con-
centrations of 12.5 ppt TEQ lipid after 6
months and 6.3 ppt TEQ lipid after 1 year.
For the 2-year breast-feeding scenario, we
assumed that concentrations in breast milk
remain at 6.3 ppt TEQ lipid from the end of
the ﬁrst until the end of the second year. 
Table 1 shows key parameters for the
dose calculation and for PK modeling for
months during the first year of life and for
key years thereafter. The dose parameters
include infant body weights as well as doses
of dioxin TEQ expressed in terms of
picograms per day by either breast-feeding or
background exposures. Breast-feeding doses
drop from 800 pg TEQ/day (242 pg
TEQ/kg-day on a body-weight basis) at birth
to 200 pg TEQ/day (18 pg TEQ/kg-day) at
1 year. We assumed that the concentration in
breast milk remains constant at 6.3 ppt TEQ
lipid (dose to infant of 200 pg TEQ/day)
from year 1 to year 2 during breast-feeding
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that the dose after breast-feeding equals
background doses; the U.S. EPA (27) deter-
mined the background dose to be 54 pg
TEQ/day (for ages 1–5 years), 59 pg/day
(6–11 years of age), 64 pg TEQ/day (12–19
years of age), and 65 pg TEQ/day (> 19
years of age). 
We used ModelMaker, Version 4.0
(ModelKinetix.com, Oxford, UK) to run the
model and generate graphic results. We used
Runge-Kutte numerical integration methods
with a specified number of steps equaling
10,000 over a 70-year simulation (about 2.5
days/step). 
The results from this exercise show the
body burdens, expressed as body lipid con-
centrations, from birth up to 70 years of age
(Figure 2) and then for a narrower time
frame, from birth to 10 years of age (Figure
3). Other results for these ﬁve scenarios are
shown in Table 4, including peak concentra-
tions in the infant, time when the peak
occurred, the area under the curve (AUC)
corresponding to different times, and the
ratio of the AUC for the breast-feeding sce-
narios and the AUC for formula feeding
only. The AUC is deﬁned as
AUC(t) = Σ c(t), [4]
where AUC(t) is the area under the curve
(parts per trillion-day) at time t and c(t) is
the lipid-based concentration in the infant
each day (parts per trillion TEQ lipid). The
AUC is a measure of accumulated exposure.
For example, 1 year at a lipid-based concen-
tration of 10 ppt would yield an AUC of
3,650 ppt-day (10 ppt × 365 days). A life-
time at an average body lipid concentration
of 10 ppt would yield an AUC of 255,500
ppt-day (10 ppt × 70 years × 365 days/year).
The AUC provides a parameter to compare
accumulated exposure for different scenarios.
For that reason, the ratios of the AUCs of
the breast-feeding scenarios and the formula-
only scenario are more important than the
AUC values themselves; these ratios are
shown in Table 4. For example, a ratio for a
particular breast-feeding scenario of 6 indi-
cates that the accumulated exposure for that
scenario is 6 times that of the formula-feed-
ing only scenario. The ratio can easily be
translated to a corresponding measure of
percent above or below the baseline scenario
of formula-feeding only. For example, if the
ratio is 6, this is equivalent to saying that the
accumulated exposure for the breast-feeding
scenario is 500% higher than the formula-
only scenario [(6–1) × 100%]; if the ratio is
0.7, this is equivalent to saying that the
accumulated exposure for the breast-feeding
scenario is 30% lower than the formula-only
scenario [–(0.7–1) × 100%]. 
The lipid concentrations are predicted to
peak at approximately 44 ppt TEQ for the 6-
month, 1-year, and 2-year scenarios (Table
4). These peaks uniformly occur at 9 weeks
of age. For the 6-week breast-feeding sce-
nario, the peak is 34 ppt TEQ lipid, which
occurs at 6 weeks of age. The lipid concentra-
tions decline after these peaks for the breast-
feeding scenarios, but the decline is slower as
the duration of breast-feeding increases. For
the 2-year scenario, the lipid concentration
stays near 40 ppt TEQ after 2 years of age
(Figure 3). The 6-week scenario shows an
increase in infant body lipid concentration to
> 30 ppt TEQ, but then shows a rapid
decline, so that it follows the formula-only
scenario fairly well after 2 years of age. All
four scenarios begin to merge near 10 years
of age (Figure 2). The rise in concentrations
seen in the later years results from the
increase of percentage body fat and the subse-
quent increase in half-life as predicted by the
elimination rate model that we used.
The AUC results in Table 4 show the
accumulated exposure to be higher for each
of the breast-feeding scenarios than for the
formula-only scenario. This exceedance
after 1 year is about a factor of 6 for breast-
feeding for ≥ 6 months. For the first 10
years of life, the accumulated exposure is
approximately 2 times higher for breast-
feeding scenarios than for the formula-feed-
ing only scenario. The ratios suggest that
breast-feeding results in a lifetime exposure
only 1.03–1.18 times higher than formula
feeding, or from 3% to 18% higher than
formula feeding only.
We conducted a sensitivity analysis to
evaluate the effect of doubling the mother’s
body burden, which we assumed would dou-
ble the dose to the infant as well as the initial
body burden of the infant. We used the 6-
month scenario for this evaluation and
assumed that the dose to the infant would
double over those 6 months and that the
infant body burden at birth was 20 ppt TEQ
instead of 10 ppt TEQ. Also, we included
one run in which the initial infant’s body
burden was 20 ppt TEQ but the dose to the
infant was the same as in the initial scenario.
This second sensitivity run evaluated only
the impact of the initial body burden.
The results of this sensitivity analysis are
shown in Figure 4. As expected, the predicted
infant body burden peak almost doubles,
from 44 ppt TEQ to just under 90 ppt TEQ.
The AUC doubles during the 6 months of
breast-feeding. However, as expected, this gap
narrows over time. After 10 years, the AUC
for the elevated exposure is about 43% higher
than the baseline 6-month scenario; after 70
years, the difference is only 9%. Figure 4 also
shows that the initial body burden assump-
tion has very little effect on modeling results.
When only the initial body burden of the
infant is increased from 10 to 20 ppt TEQ
lipid, the peak concentration at 9 weeks
increases slightly to 49 ppt TEQ with the
higher initial body burden, but the AUC is
only marginally different for the baseline 
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Figure 2. Demonstration of the model for evaluat-
ing impacts on lipid concentrations of infants
resulting from various nursing scenarios during a
lifetime.
Figure 3. Demonstration of the model for evaluat-
ing impacts on lipid concentrations of infants
resulting from various nursing scenarios during
the ﬁrst 10 years of life. 
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Table 4. Results of pharmacokinetic modeling for formula feeding and four breast-feeding scenarios.
Breast-feeding scenarios
Description of output Formula 6 weeks  6 months 1 year 2 years
Peak concentration (pg/g lipid) 13.0 34.1 44.3 44.3 44.3
Peak (time after birth)  9 years 6 weeks 9 weeks 9 weeks 9 weeks
AUC after 1 year 2,168 5,989 12,129 13,645 13,645
AUC after 10 years 39,433 46,516 62,696 73,183 86,370
AUC after 70 years 275,419 282,654 299,304 310,210 324,202
AUCBF/AUformula
1 year — 2.8 5.6 6.3 6.3
10 years — 1.2 1.6 1.9 2.2
70 years — 1.03 1.09 1.13 1.18
BF, breast-feeding.6-month feeding scenario. The lack of
meaningful impact of the initial infant body
burden is also seen in Figure 3, which shows
all of the evaluation scenarios. The infant
body burden appears to quickly adjust to the
dose: a high dose causes the infant body bur-
den to increase quickly and a low dose, such
as with formula feeding, causes the infant
body burden to drop to a level supported by
that dose. In short, the mother’s body bur-
den certainly affects the dose received by the
child, and although the initial body burden
of the infant is also affected (we presume),
this does not appear to be critical to the
infant’s subsequent body burden in the ﬁrst
weeks and months of life. 
Summary and Future
Research Needs
In this paper, we evaluated infant exposure
to dioxin-like compounds via consumption
of breast milk. Limited measurements in the
literature showed that breast-fed infants had
higher body burdens compared to formula-
fed infants by up to one order of magnitude.
Levels in breast-fed infants ranged from near
10 ppt TEQ lipid to > 50 ppt TEQ lipid,
with levels in infants in a region known to
be affected by a nearby source of dioxin
release (metals reclamation plant) > 100 ppt
TEQ. In contrast, formula-fed infants were
almost always < 10 ppt TEQ and, in some
cases, < 5 ppt TEQ. 
We used a simple, one-compartment PK
model to translate the dose of dioxin TEQs
received by the infant via breast-feeding to a
body burden, expressed as a lipid concentra-
tion. The PK model, while simplistic in both
structure and assignment of parameters,
nonetheless appears to predict TEQ body
burdens that are within the range of observed
body burdens. In a limited model validation
exercise, the model predicted an average
infant body burden of 26 ppt TEQ lipid for
six infants who had been breast-fed, whereas
the average observed body burden for those
six infants was 24 ppt TEQ. 
We used this modeling framework to
evaluate different breast-feeding regimes,
including formula feeding only, and breast-
feeding for periods of 6 weeks, 6 months, 1
year, and 2 years. First, we calculated tempo-
rally varying estimates of dose. Assuming a
starting mother’s milk concentration of 25
ppt TEQ lipid, we estimated infant doses to
be 242 pg TEQ/kg-day at birth and 18 pg
TEQ/kg-day after 1 year of breast-feeding.
Using the PK model, we predicted that a
peak infant concentration of 44 pg TEQ/g
lipid would occur at 9 weeks of age. We
found that the accumulated exposure to a
child who had been breast-fed was signifi-
cantly higher than a formula-fed only infant
(where it was assumed that the infant dose
via formula ingestion was similar to typical
background exposures for young children).
Specifically, ≥ 6 months of breast-feeding
would result in accumulated exposure 6
times higher than a formula-fed infant dur-
ing the first year of life, and this accumu-
lated exposure would still be twice as high
after 10 years. Over a lifetime, breast-feeding
results in an accumulated exposure that is
3–18% higher than for a formula-fed infant,
depending on the length of time of breast-
feeding. Using a sensitivity analysis exercise,
we demonstrated that the model is linearly
responsive to dose received by the infant—
doubling of the dose results in a doubling of
infant impacts. This sensitivity exercise also
showed that the model is relatively insensi-
tive to the initial body burden of the infant.
The infant’s body burden adjusts very
rapidly to the dose received: it declines
quickly if the infant receives a low dose, such
as from formula-feeding, and rises quickly if
the infant has a much higher dose, such as
from breast-feeding.
The model parameter of most uncer-
tainty, and of significant impact to model
results, is the overall dissipation rate assigned
to TEQs. Empirical data in the literature has
focused on the dissipation of TCDD in
adults, with half-lives typically in the range
of 7 years. Our assignment of this parameter
for modeling infancy through adulthood was
a hybrid of two approaches in the literature
developed for PK modeling of TCDD. The
model we used for infancy had half-lives < 1
year for this initial period in life, whereas the
other model used for adulthood had half-
lives from 6 to 20 years. Limited model vali-
dation suggested that the dissipation rate of
TEQ in the infant was significantly higher
(equivalently, the half-life was lower) than
implied from data of TCDD in adults. 
The U.S. EPA, in its draft reassessment
of dioxin and related compounds (23),
concluded that body burden is the most
appropriate exposure matrix for evaluating
the health consequence of exposure to
dioxin-like compounds. Therefore, although
the dose received by the infant via breast-
feeding can be tens to even hundreds of times
higher than the dose to an adult (on a body
weight basis), the resulting body burden of
the infant is within the range observed for
adults. Speciﬁcally, even the peak body bur-
den for the breast-feeding scenarios (44 ppt
TEQ) is within a factor of 2 of the average
adult body burden of 25 ppt TEQ. This ele-
vation in infant body burden of dioxin-like
compounds as a result of breast-feeding has
been identiﬁed by several researchers in addi-
tion to the U.S. EPA (2,3,4,19,22); some of
these studies have also concluded that the
body burdens of breast-fed versus formula-
fed infants have merged after a few years
(3,4). However, the health consequence of
this temporary elevation of infant body bur-
dens is uncertain. The U.S. EPA (23), along
with several others such as the American
Academy of Pediatrics (25), concluded that
the benefits of breast-feeding outweigh any
potential risks associated with this practice,
and they readily recommend breast-feeding
over formula-feeding. 
Future work on this PK model should
focus on developing congener-specific half-
lives that consider not only the differences in
the absorption of these congeners in the
body but, equally important, the metabolism
of these congeners as a function of age.
Additional data on infant impacts, such as
infant blood TEQ concentrations to study
the temporal change in infant body burden
during the first weeks and months of life,
would also be helpful in future validation of
this and similar models. 
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